Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01185366 · ClinicalTrials.gov registry record · Phase 2
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT01185366: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01185366 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 73 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01185366, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to compare the effectiveness of Afinitor (everolimus) and Sutent (sunitinib) for the treatment of advanced renal cell carcinoma (kidney cancer). The safety of each treatment will also be studied.
Interventions
- DRUG Everolimus
- DRUG Sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2010-08 |
| Est. Completion | 2019-09-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01185366
The ClinicalTrials.gov registry entry for NCT01185366 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01185366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01185366 about?
NCT01185366 is a clinical study titled "Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma". The goal of this clinical research study is to compare the effectiveness of Afinitor (everolimus) and Sutent (sunitinib) for the treatment of advanced renal cell carcinoma (kidney cancer). The safety of each treatment will also be studied.
What is the current status of trial NCT01185366?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2010-08. Estimated completion is 2019-09-09.
What interventions are being tested in trial NCT01185366?
The interventions under investigation include: Everolimus (DRUG), Sunitinib (DRUG).
Who is sponsoring clinical trial NCT01185366?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.